EDITORIAL SECTIONS
RESEARCH & DEVELOPMENT
Adopting the Power of AI to Drug Development Projects
A tremendous amount of documentation is created throughout the clinical trial lifecycle
CLINICAL TRIALS
Real-world Evidence
Hearing the diagnosis from the doctor that your child has spinal muscular atrophy SMA
MANUFACTURING
Just in Time Manufacturing Creating more sustainable supply chains
Drug development has transformed immeasurably over the past decade Even before the Covid pandemic and the conflict in Ukraine
Information Technology
Challenges and Advantages of Using Artificial Intelligence in Pharma
Many advanced largescale AI initiatives still need to be proved successful in Pharma
KNOWLEDGE BANK
Interviews
MAb Aggregation: A Problem Within the Biopharmaceutical Industry
Associate Professor, Trinity College Dublin, Ireland
Educated at Seoul National University UC Berkeley and Purdue University with postdoctoral research at the University of Oxford KH Mok specializes in utilising biomolecular NMR spectroscopy to protein foldingmisfoldingaggregation research Coauthor of publications in Nature Nature Communications Nature Immunology PNAS and others he currently serves as a Eureka Independent Evaluation Panel member tec...
Articles
Government Investment in AI Capabilities will Cement Singapore’s Position as a Premier Clinical Trial Location
As Asia establishes itself as the global hub for clinical trials Singapore is bolstering its position as the preferred location for these trials to take place The countrys strong RD capabilities talent pool world class healthcare infrastructure and robust regulatory
Research Insights
Time-dependent Vaccine Efficacy Estimation Quantified by a Mathematical Model
In this paper we calculate the variation of the estimated vaccine efficacy VE due to the timedependent force of infection resulting from the difference between the moment the Clinical Trial CT begins and the peak in the outbreak intensity
Case Studies
Heat Stable Hepatitis B vaccine
Partner Since Arecor has collaborated with PATH an international global health nonprofit organisation on the development of heat stable vaccines using the ArestatT technology Stabilisation of hepatitis B vaccine one of the many vaccines successfully st
Techno Trends
Renibus Therapeutics Introduced First-of-its-Kind RBT-1 for Reducing Post-Operative Complications
Renibus Therapeutics has introduced firstofitskind RBT to reduce the risk of postoperative complications in patients undergoing cardiothoracic surgery
White Papers
Cloud Computing in the Laboratory Informatics Solutions and Validation Approaches
In the modern business environment, a significant portion of work is conducted using computerized systems. Many solutions are used to complete tasks, including simple desktop programs like email and Microsoft Office to enterprise-wide, global systems like ERP (Enterprise Resource Planning), MES (Manufacturing Execution System), and LIMS
TOP ARTICLES
Impact Assessment of US Tariff Threat on Indian Healthcare Export
Dr. M. Aamir Mirza is working as an Assistant Professor in the Department of Pharmaceutics, Jamia Hamdard, an NIRF Rank 1 institute and a NAAC ‘A+” grade deemed to be University. He has a multifaceted career portfolio adorned with both industry and academic accomplishments. During his industry stay he became a seasoned scientist and dealt with challenging NCE/NDA development. He is on advisory boards of some international research-based companies of India, New Zealand and Europe. Academics and Research being close to his heart, he has published more than 110 manuscripts in the journals of international repute and has been granted 02 Indian patent and filed for 04. He has contributed several chapters in books published by reputed authors like Elsevier and Bentham. He is amongst the very few scientists globally who has an expertise in Humic substances research. A well-travelled scientist; he has delivered scientific addresses in countries like USA, Austria, Japan, Netherlands, Turkey, Estonia, Spain and Russia. He has been Elite Fellow at University of Malaya (Malaysia) for the last 5 years where he takes classes on the topics related to industrial pharmacy.
How Ready are Cellulose Nanocrystals in Delivery of Anticanceragents?
Researcher, Donghua University
Probiotics as live Biomolecules to Manage Sleep Disorders
Sumel Ashique, Assistant Professor at Bharat Technology, is an accomplished pharmaceutical scientist with 150+ publications, 5 patents, and expertise in drug delivery and nanotechnology. He serves as a reviewer and guest editor for reputed journals and is currently pursuing a Ph.D. at Lovely Professional University, Punjab.
Mohini Mondal, Assistant Professor at Bharat Technology, is a dedicated pharmaceutics academic and researcher. With an M. Pharm and ongoing Ph.D., she specializes in drug delivery systems and holds an IP for an innovative ocular gel. Her work bridges teaching and research, shaping future pharmaceutical professionals.
Multi-Target Directed Ligands and Lipidomics Approach for Glioblastoma Drug Discovery
Dr. Stevan Pecic is an assistant professor at the Department of Chemistry and Biochemistry at California State University, Fullerton. His main research interests and assignments are focused on the identification of novel inhibitors of enzymes involved in lipid metabolism and their evaluation as potential therapeutics in pain management.
Xiaohui Weng earned a bachelor’s in chemistry from Fordham University and recently completed her master’s degree working in Dr. Pecic medicinal chemistry lab at California State University, Fullerton. Her current research focuses on target identification for glioblastoma and the synthesis of new anti-cancer drugs.
Michael Gonzalez is a graduate student pursuing a master’s in chemistry at California State University Fullerton. Currently he also interns at a start-up biotech company, playing an important role in chemistry development for their high-throughput macrocyclic synthesis platform.
Arya obtained his Hon. BSc. in Human kinetics from University of Guelph, where he completed a summer internship at Dr. Ghavami’s lab at University of Manitoba. Arya then pursued a double major from York University majoring in Neuropsychology. Arya’s research under the supervision of Dr. Ghavami resulted in four publications, and he has since been involved in the review and publication process of manuscripts in highly regarded journals. Arya is currently entering the second year of his Doctor of Dental Surgery program at the Faculty of Dentistry, University of Toronto.
Dr. Amir Barzegar Behrooz is a cancer researcher and postdoctoral fellow at the College of Pharmacy, University of Manitoba. His work focuses on various aspects of cancer biology, particularly glioblastoma. His work focuses on targeted cancer therapy, and theranostic targets in cancer cells via Onco-Multi-OMICS.
Dr. Rui Vitorino, Principal Investigator at the University of Aveiro, specializes in OMICS, proteomics, and bioinformatics. His research on biofluids like saliva and urine aims to uncover disease pathways and biomarkers. Vitorino's multidisciplinary approach enhances early disease detection, influencing molecular and cell biology studies significantly.
Dr. Ghavami, an Associate Professor at the University of Manitoba, specializes in apoptosis, autophagy, and unfolded protein response regulation. With over 300 publications and numerous awards, he's globally recognised. Affiliated with institutions worldwide, he serves as Associate Editor for multiple scientific journals.
AI Cures
Anuradha Singh is an Assistant professor at the Department of Chemistry, S Khanna Girls’ Degree College, University of Allahabad. She is well versed in synthetic chemistry, computer-aided drug design and other techniques used in the field of medicinal chemistry. Dr Singh has published more than 30 research papers/book chapters, in addition to several articles, in journals/books of national and international repute. She has been selected for the prestigious Indian National Science Academy's Visiting Scientist fellowship in 2023. She is a member of several national bodies and referee to various national/ international journals. She successfully led research projects funded by DST and UGC, demonstrating strong leadership and project management skills.
press releasesRead more...
Asia–US Clinical Data Collaboration Built on IHH's Clinical Data
Mitsui Co Ltd Mitsui Head Office Tokyo President and CEO Kenichi Hori has entered a service agreement with Oncoshot Pte Ltd Oncoshot on the utilization of Oncoshots proprietary clinical
Teijin, Teijin Regenet and Shinshu University Hospital Launch Joint Research to Strengthen CAR-T Cell Therapy Manufacturing Capabilities in Japan
Teijin Limited Teijin Regenet Co Ltd and Shinshu University Hospital today announced that they have entered into a joint research agreement regarding manufacturing technologies for cell and gene
VVMF, Australia’s First Viral Vector CDMO Receives TGA Manufacturing Licence
Viral Vector Manufacturing Facility Pty Ltd VVMF Australias first viral vector Contract Development and Manufacturing Organisation CDMO advises that the Therapeutic Goods Administration TGA
Oral insulin drug achieves a critical milestone
University of Sydney biotechnology spinout Endo Axiom is conducting its first study in human subjects to assess the safety and tolerability of different doses of oral insulin in healthy volunteers
Transcenta Therapeutics and WuXi Biologics Enter into Strategic Collaboration to Accelerate Commercialization of HiCB Continuous Bioprocessing Technologies
Transcenta Therapeutics HKEX a global clinicalstage biopharmaceutical company with fully integrated capabilities in discovery RD and process development of antibodybased therapeutics
1cBio and Lee's Pharmaceutical Holdings Limited Enter into Exclusive Licensing Agreement to Develop and Commercialize 1cBio's PARP1 Inhibitor OC-3 for Oncology in Greater China
cBio a biopharmaceutical company focused on discovering and developing innovative therapies for serious and underserved conditions including oncology and metabolic diseases and Lees Pharmaceutical
EventsRead more...
14 - 15
Sep 202616th American DDF Summit
Omni Boston Hotel at the Seapo...
14 - 16
Sep 202615 - 17
Sep 2026COPD Drug Development Summit 2026
Street, Boston, MA 02210, USA
21 - 23
Sep 2026Cell & Gene Therapy World Conference
Miami, Florida, USA
21 - 23
Sep 2026Cancer R&D World Conference
Hilton Garden Inn Miami Dolphi...
22 - 23
Sep 2026PDA Advanced Parenteral Therapeutics & Quality Summit
Illume Hotel Taipei, Taiwan
22 - 24
Sep 2026InsurInnovator Connect Asia
Singapore
28 - 01
Sep 2026Discovery on Target 2026
Boston, MA, USA
LATEST NEWSRead more...
CordenPharma Expands Aseptic Fill-Finish Capacity to 500 Million Sterile Injectable Units Annually
CordenPharma is expanding its sterile injectable manufacturing capacity at its Caponago site in Milan Italy through a multiyear investment programme
Exegenesis Bio Enters into Collaboration with Modalis to Advance MDL-201 for Duchenne Muscular Dystrophy
Exegenesis Bio and Modalis Therapeutics have entered into a research collaboration and licence agreement to advance MDL an investigational treatment for Duchenne muscular dystrophy DMD
Schrödinger Forms Tectora Therapeutics to Advance Immunology and Inflammation Programmes
Schrdinger has announced the formation of Tectora Therapeutics The company was cofounded by Schrdinger New Enterprise Associates NEA and RA Capital Management
MannKind and Rose Pharma Partner to Develop Inhaled GLP-1 for Weight Management
MannKind and Rose Pharma have entered into a worldwide licensing and collaboration agreement to develop ROSE Technosphere an investigational inhaled GLP therapy for weight management
Rezubio Advances RZ-520 into Phase 1 Clinical Trial Following FDA and NMPA Clearances
Rezubio has announced the first cohort dosing in its Phase clinical trial of RZ following Investigational New Drug IND clearances from the US Food and Drug Administration FDA and Chinas National Medical
ZANVASTRO approved by FDA as first disease-modifying treatment for Alexander disease
Ionis Pharmaceuticals has received approval from the US Food and Drug Administration FDA for ZANVASTRO zilganersen to treat Alexander disease AxD in paediatric and adult patients